The combined removal of GOLM1, PSCA and CFD led to the derivation of a seven-member mRNA panel (FOLH1, HPN, CD24, TMPRSS2-ERG overexpressed; ITSN1, ANXA3, SLC45A3 underexpressed) with increased significance for prediction of prostate cancer over the 10-member panel (seven mRNA panel: OR = 2.237, 95% CI = 1.4036–3.5656, p value = 0.0007; 10 mRNA panel: OR = 1.636, 95% CI = 1.1808–2.2663, p value = 0.0031) and the previously derived four mRNA panel (OR = 1.136, 95% CI = 1.0479–1.2313, p value = 0.002). The gene discussed is ANXA3; the disease is prostate cancer.